For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Chugai Puts Off NHI Price Listing for Kadcyla, Agreement Not Reached
November 15, 2013
- Otsuka Holdings Notches Double-Digit Sales Growth in April-September, Weaker Yen Comes as Boon
November 14, 2013
- Chugai Obtains Exclusive Commercialization Rights for Anamorelin in Europe from Helsinn
November 14, 2013
- Kenko.com Sues Government to Affirm Right to Sell Prescription Drugs Online
November 14, 2013
- Generic Market Continues to Grow, Three Generic-Only Makers’ Sales Up 8.8%
November 13, 2013
- Kyowa Kirin Ceases Japan PII Trial on Chronic Kidney Disease Agent
November 13, 2013
- JV of DSP, Japan BCG to Develop New TB Vaccines with NIBIO, US NPO
November 13, 2013
- Antiepileptic Drug Eslicarbazepine Granted US Approval: DSP
November 13, 2013
- Commercial Director Feliciano to Become President of Merck Serono Japan
November 12, 2013
- Eylea Bests Lucentis in Ophthalmic VEGF Inhibitor Market; Santen Ups Sales Outlook for Drug
November 12, 2013
- GLP-1 Dulaglutide “Catalyst of Growth,” SGLT-2 Empagliflozin Will Be Successful Despite Later Launch: Lilly Diabetes President
November 12, 2013
- Ethical Drug Sales Up 5.3% in September: Crecon Report
November 12, 2013
- Eisai to Develop Belviq for Japan Market via Expanded Deal with Arena
November 12, 2013
- NCC, Sanofi Forge Alliance in Anticancer Drug R&D
November 12, 2013
- Eisai Enters Global Agreement with Broad Institute of US to Develop New Drugs for NTDs and Tuberculosis
November 12, 2013
- 4 Major Wholesalers’ Operating Margins Stay on Recovery Path, But Average Settlement Rate at Mere 72% at Sept.-End
November 11, 2013
- Nichi-Iko Pres. Airs Frustration with Sanofi over Cancellation of Biosimlar Codevelopment Deal
November 8, 2013
- Nichi-Iko Pitting Allegra AG against Other Generics, Not Originator: Pres. Tamura
November 8, 2013
- Bristol-Myers Files NDA for DCV/ASV Combination Therapy for Treatment of Hepatitis C in Japan
November 8, 2013
- MTPC Aims to Reach Midterm Targets through Royalties from Licensed Products, But Success Likely to Depend on Performance in Domestic Market
November 8, 2013
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…